2601_T02_TSI_03 Higher Order Structure
- W związku z realizacją projektu rozwoju kandydata na lek o tytule „“Development of first-in class antibody therapy for immunotherapy in metastatic melanoma, using Companion Diagnostics (CDx) patient stratification for treatment with the immune stimulating anti-CD270 antibody.″ w ramach konkursu Rozwój medycyny celowanej lub personalizowanej na bazie terapii komórkowych lub produktów białkowych, organizowanego przez Agencję Badań Medycznych, ogłaszamy zapytanie ofertowe: na przeprowadzenie analizy struktury wyższego rzędu JJP-1008, monoklonalnego przeciwciała IgG4κ.
- Zapytanie ofertowe (RFP) do pobrania znajdą państwo pod tym linkiem [LINK].
Termin składania ofert: 06.02.2026.- Termin składania ofert został wydłużony do 09.02.2025
- Oferty, pytania i kontakt w związku z zapytaniem proszę kierować na adres:
Otrzymane pytania dotyczące specyfikacji zamówienia:
- Under the terms of the tender, do you allow analyses that would be subcontracted by the bidder? For certain designations—specifically CD and FTIR—we collaborate with our subcontractors, but I’m not sure if such an arrangement fits within the tender conditions.
Odpowiedź:In the course of this proceeding, we allow for the possibility of subcontracting selected analyses to subcontractors. However, please note that:
The Supplier may not subcontract any of its rights or obligations without the prior written consent of JJPB.
The Supplier shall ensure that all subcontracting agreements are performed on terms no less restrictive than those specified in the Agreement entered into with JJPB.
The Supplier is responsible for the actions and omissions of each subcontractor as if such actions and omissions were performed by the Supplier itself.
The Supplier remains responsible to JJPB for the provision of Services or Results.
Accordingly, we kindly request that you indicate in your offer which elements of the order will be performed directly by you and which by subcontractors, as well as identify those subcontractors.